Risk factors for myocarditis associated with immune checkpoint inhibitors using real-world clinical data.

被引：0
|
作者：
Jain, Prantesh
Bugarin, Jahir Gutierrez
Guha, Avirup
Jain, Chhavi
Shen, Tingke
Stanevich, Ilya
Margevicius, Seunghee P.
Fu, Pingfu
Liu, Fang
Nikore, Vipan
Mangla, Ankit
De Lima, Marcos J. G.
Velcheti, Vamsidhar
Barnholtz-Sloan, Jill
Dowlati, Afshin
机构：
[1] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA
[4] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[5] Cleveland Clin, Cleveland, OH 44106 USA
[6] Case Comprehens Canc Ctr, Cleveland, OH USA
[7] NYU Langone, Perlmutter Canc Ctr, New York, NY USA
[8] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA
[9] Case Western Reserve Univ, Sch Med, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA
[10] Case Western Reserve Univ, Case Comprehens Canc Ctr, Univ Hosp Seidman Canc Ctr, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15100
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States (vol 6, 100252, 2021)
    Jain, P.
    Bugarin, J. Gutierrez
    Guha, A.
    Jain, C.
    Patil, N.
    Shen, T.
    Stanevich, I.
    Nikore, V.
    Margolin, K.
    Ernstoff, M.
    Velcheti, V.
    Barnholtz-Sloan, J.
    Dowlati, A.
    ESMO OPEN, 2021, 6 (06)
  • [32] Clinical Characteristics of Toxicities of Immune Checkpoint Inhibitors and Their Impact on Efficacy in Solid Cancers: An Analysis of Real-World Data in Moroccan Patients
    Batlamous, Badiaa
    Lkhoyaali, Sihame
    Omri, Loubna
    Nguema-Mipaka, Magaly-Gwen-Farnely
    Khalis, Mohamed
    Inrhaoun, Hanane
    Naciri, Sarah
    El Ghissassi, Ibrahim
    Mrabti, Hind
    Boutayeb, Saber
    Errihani, Hassan
    JCO GLOBAL ONCOLOGY, 2025, 11
  • [33] Patterns of immune checkpoint inhibitor utilization and PD-L1 testing in advanced gastroesophageal cancers using real-world data.
    Kaur, Jasmeet
    Zhang, Li
    Hasler, Jill S.
    Dotan, Efrat
    Cann, Christopher G.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 370 - 370
  • [34] Assessment of Risk-Benefit Balance of Immune Checkpoint Inhibitors in a Real-World Lung Cancer Population
    Mehta, Hemalkumar B.
    Segal, Jodi
    Heyward, James
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 167 - 168
  • [35] Khorana risk score in lung cancer patients treated with immune checkpoint inhibitors: a real-world study
    Song, Junmin
    Morgan, Ahmed Ashraf
    Abram, Ana Maria Diaz
    Hong, Daniel
    Kim, Gagi
    Li, Wing Fai
    Ahn, Jaeun
    Chang, Yu
    Chi, Kuan-Yu
    Chiang, Cho-Han
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2025, 58 (04) : 497 - 502
  • [36] Lessons learned from the reimbursement policy for immune checkpoint inhibitors and real-world data collection in Taiwan
    Huang, Li Ying
    Gau, Churn-Shiouh
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 37 (01)
  • [37] Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
    Nishimura, Tadashi
    Fujimoto, Hajime
    Okano, Tomohito
    Naito, Masahiro
    Tsuji, Chikashi
    Iwanaka, Soichi
    Sakakura, Yasumasa
    Yasuma, Taro
    D'Alessandro-Gabazza, Corina N.
    Oomoto, Yasuhiro
    Gabazza, Esteban C.
    Kobayashi, Tetsu
    Ibata, Hidenori
    CANCERS, 2022, 14 (12)
  • [38] Adverse drug events of immune checkpoint inhibitors - Preliminary results of a retrospective real-world data analysis
    Auch, L.
    Hug, B.
    SWISS MEDICAL WEEKLY, 2024, 154 : 19S - 19S
  • [39] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Kang Chen
    Wei Wei
    Lei Liu
    Zhu-Jian Deng
    Le Li
    Xiu-Mei Liang
    Ping-Ping Guo
    Lu-Nan Qi
    Zhi-Ming Zhang
    Wen-Feng Gong
    Shan Huang
    Wei-Ping Yuan
    Liang Ma
    Bang-De Xiang
    Le-Qun Li
    Jian-Hong Zhong
    Cancer Immunology, Immunotherapy, 2022, 71 : 1063 - 1074
  • [40] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Chen, Kang
    Wei, Wei
    Liu, Lei
    Deng, Zhu-Jian
    Li, Le
    Liang, Xiu-Mei
    Guo, Ping-Ping
    Qi, Lu-Nan
    Zhang, Zhi-Ming
    Gong, Wen-Feng
    Huang, Shan
    Yuan, Wei-Ping
    Ma, Liang
    Xiang, Bang-De
    Li, Le-Qun
    Zhong, Jian-Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1063 - 1074
12345